-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8by Yoshikawa Y, Shoji T, Kanno J, Ibuki H, Ozaki K, Ishii H, Inami H, Shinoda K“...Clinical Ophthalmology...”
Published 2021-09-01
Get full text
Article -
9
-
10by Kowalski R, Kamyar R, Rhee M, Mammen A, Dhaliwal D, Romanowski EG, Jhanji V, Eller AW“...Clinical Ophthalmology...”
Published 2021-09-01
Get full text
Article -
11by Figueira J, Henriques J, Carneiro Â, Marques-Neves C, Flores R, Castro-Sousa JP, Meireles A, Gomes N, Nascimento J, Amaro M, Silva R“...Clinical Ophthalmology...”
Published 2021-07-01
Get full text
Article -
12
-
13by Kasetsuwan N, Uthaithammarat L, Piyacomn Y, Reinprayoon U, Chatchavalvanich C, Panchaprateep R“...Clinical Ophthalmology...”
Published 2021-07-01
Get full text
Article -
14
-
15by Moshirfar M, Ellis J, Beesley D, McCabe SE, Lewis A, West Jnr WB, Ronquillo Y, Hoopes Snr P“...Clinical Ophthalmology...”
Published 2021-07-01
Get full text
Article -
16
-
17
-
18by Vukich JA, Ang RE, Straker BJK, Janakiraman DP, Smith PJ, Batlle JF, Waltz KL“...Clinical Ophthalmology...”
Published 2021-07-01
Get full text
Article -
19Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edemaby Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA“...Clinical Ophthalmology...”
Published 2021-07-01
Get full text
Article -
20